| Similar Articles |
|---|
 |
The Motley Fool
August 4, 2006
Stephen D. Simpson |
SilverHawk Flying Just Fine, Thanks With med-tech company FoxHollow Technologies, there is growth and risk in equal measure. Investors, take note.   |
The Motley Fool
May 5, 2006
Stephen D. Simpson |
FoxHollow-ed Out Worries about guidance may be giving investors a second crack at this med-tech stock. |
The Motley Fool
December 29, 2006
Matthew Crews |
FoxHollow: Scale Is Critical Can this medical-device maker be a long-term success, or is it just a one-hit wonder? Investors, take note. |
The Motley Fool
May 4, 2007
Billy Fisher |
In Search of New Prey at FoxHollow The medical device maker reported a 6% increase in revenues on a year-over-year basis for its first-quarter. Investors, take note. |
The Motley Fool
February 17, 2006
Stephen D. Simpson |
AtriCure Sends Investors' Hearts Aflutter AtriCure addresses a real market, but faces a typically rocky road. But executing on a big opportunity can mean ample rewards for patient investors. |
The Motley Fool
February 15, 2007
Billy Fisher |
Taking FoxHollow's Pulse The medical-device maker gets a checkup from the market. Results were mixed, although the stock was trading down 4%. |
The Motley Fool
April 19, 2006
Stephen D. Simpson |
St. Jude Lives and Learns Though dynamics in the ICD market caught it by surprise, this is still a quality med-tech company. Investors, take note. |
The Motley Fool
January 30, 2006
Stephen D. Simpson |
A Bard's Tale The advanced medical technology company's stock already reflects new products' potential. Still, life in the med-tech sector could get more interesting in the coming quarters. Investors, take note. |
BusinessWeek
December 6, 2004
Gene G. Marcial |
Boston Scientific: Anemic -- For Now Boston Scientific is far from robust -- since its summer recall of 100,000 coronary stents and since its lowered fourth-quarter profit forecast. Analysts quickly cut estimates, driving shares down from 46 in May to 33.36 on Nov. 23. |
The Motley Fool
July 5, 2006
Glenn Brandys |
FoxHollow's SilverHawk Won't Soar Cost, time, and competition are holding back the med-tech's device for treating artery disease. Investors, take note. |
The Motley Fool
January 17, 2006
Stephen D. Simpson |
High-Stakes Medical Device Chicken Boston Scientific has upped the ante again. Are they bluffing? Their latest offer is $80 a share -- $42 in cash and $38 in stock. Let's hope the board knows what it is doing, because it is staking the company on this. |
The Motley Fool
April 21, 2006
Stephen D. Simpson |
Bard Rolls On Nothing flashy here, but at the right price, this would be an interesting med-tech play. Investors, take note. |
The Motley Fool
February 21, 2007
Billy Fisher |
Scorching Sales Growth at ev3 Profits should be arriving soon for this medical device maker. The medical breakthroughs already are. Investors, take note. |
The Motley Fool
September 29, 2006
Brian Lawler |
Merck Likes FoxHollow The pharmaceutical giant signs another collaborative research agreement with the small-cap company. Investors, take note. |
The Motley Fool
December 5, 2005
Stephen D. Simpson |
Boston Scientific's Bold Move Acquiring Guidant would be risky, but it would give Boston Scientific exactly what it needs. It will be curious to see how J&J responds to this deal. Investors, take note. |
The Motley Fool
May 4, 2006
Stephen D. Simpson |
Aspect Won't Put You to Sleep High valuation of this med-tech company all but guarantees that the stock will see some volatility. |
The Motley Fool
February 5, 2007
Ryan Fuhrmann |
Boston Scientific's Unscientific Outlook There's still uncertainty as the med-tech company blends an acquisition and deals with controversy. Investors, take note. |
The Motley Fool
November 10, 2006
Billy Fisher |
FoxHollow Taken to the Cleaners The medical-device maker's reduced guidance leaves investors steamed. |
The Motley Fool
July 31, 2006
Stephen D. Simpson |
Can Boston Scientific Get It Right? To boost investor confidence, management must first prove itself. |
The Motley Fool
June 29, 2006
Jim Mueller |
Guidant, Devices, and Recalls, Oh My! To repair its acquisition's good name, Boston Scientific must quickly fix Guidant's problems. One analyst sees annual growth for Guidant's devices in the 10% to 15% range. No one knows how accurate that will prove to be, but it certainly provides hope for the troubled acquisition. |
BusinessWeek
June 20, 2005
Spencer E. Ante |
Powering Through Clogged Arteries FoxHollow's SilverHawk is a promising alternative to stents and bypass surgery. |
The Motley Fool
June 13, 2006
Jim Mueller |
Foolish Investing and Boston Scientific In having bought Guidant, Boston Scientific might end up paying more than just the price. Investors, take note. |
The Motley Fool
December 8, 2004
Dave Marino-Nachison |
J&J Guided to Guidant? Medical device investors felt their hearts skip as executives told The New York Times the two companies may be set to merge. |
The Motley Fool
July 27, 2006
Stephen D. Simpson |
Growth Ingrates Dump Intuitive Surgical Despite today's sell-off, Intuitive Surgical remains a red-hot grower in the med-tech space. |
The Motley Fool
January 13, 2006
Stephen D. Simpson |
Once More With Guidant In the ongoing game of tit-for-tat, Boston Scientific ups its bid for Guidant. This battle will ultimately be decided by the 800-pound gorilla that is J&J. Investors, take note. |
The Motley Fool
November 9, 2006 |
FoxHollow Technologies: Fool by Numbers The med-tech company released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
February 1, 2010
Brian Orelli |
Now That's Some Expensive Risk Mitigation Boston Scientific avoids a trial -- but at a dear cost. |
The Motley Fool
May 2, 2007 |
Product Revenue Falls at FoxHollow Technologies: Fool by Numbers The medical device maker released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
November 9, 2009
Brian Orelli |
Guidant: The Gift That Keeps on Giving And not in the good way. Last year, Boston Scientific took a whopping $2.7 billion goodwill writedown because it had to downgrade the value of what it got in acquiring Guidant. |
The Motley Fool
May 24, 2006
S.J. Caplan |
Goodbye, Guidant Publicity woes drive Boston Scientific to ditch the Guidant name. In the meantime, Boston Scientific wants to capitalize on its entry into the ICD market, an area experiencing double-digit sales growth. Investors, take note. |
The Motley Fool
February 20, 2007 |
FoxHollow Technologies Breathing OK: Fool by Numbers The medical device maker released fourth-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
